• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Early alteplase treatment leads to better stroke outcomes regardless of age or stroke severity

byDevin MillerandStefan Trela
August 6, 2014
in Emergency, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Alteplase (recombinant tissue plasminogen activator, or rtPA) administration within 4.5 hours hours following the onset of an ischemic stroke improves the odds of good stroke outcomes regardless of age or stroke severity, with greater proportional benefits seen with earlier treatment. 

2. Administration of alteplase carried an increased risk of fatal intracranial hemorrhage within the first few days following treatment. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Intravenous administration of alteplase within 4.5 hours following the onset of an ischemic stroke has been shown to be beneficial in many patients. Controversy exists, however, regarding alteplase treatment either within 3 or 4.5 hours, after 4.5 hours, in patients greater than 80 years of age, or in patients with mild or severe strokes. This study aimed to clarify these controversies by utilizing a meta-analysis that combined data from several large randomized trials comparing alteplase with placebo or open control.

The results showed that alteplase can be used in patients of any age group or stroke severity up to 4.5 hours after ischemic stroke onset with greater proportional benefits seen with earlier treatment. However, treatment with alteplase also led to increased risks of fatal intracranial hemorrhage within the first few days following treatment. Strengths of this analysis include its large study population as well as that individual data sets could be extracted for many of these patients. Additionally, the large number of patients over the age of 80 allowed for better representation of the general population and comparison to treatment in patients under 80 years of age. A drawback to this study is that the estimates of intracranial hemorrhage may be exaggerated due to broad definition utilized by one of the studies included in the analysis. The authors conclude that despite early increased risks of fatal intracranial hemorrhage, alteplase significantly improves the long-term odds of a good stroke outcome at 3-6 months.

This study was funded by the UK Medical Research Council, British Heart Foundation, University of Glasgow, and University of Edinburgh

Click to read the study, published today in The Lancet

RELATED REPORTS

Bivalirudin during and post-percutaneous coronary intervention reduces bleeding and mortality compared to heparin monotherapy

The Scan by 2 Minute Medicine®: the New Cost of Insulin, Beyond IVF, the Spotlight on RSV and Influenza, and Theranos Founder Sentenced to 11 Years!

#VisualAbstract: Intensive blood pressure control post-endovascular thrombectomy after acute ischemic stroke linked with worse clinical outcomes

Relevant Reading: The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

In-Depth [meta-analysis]: This meta-analysis included data from 6,756 different patients from nine randomized phase 3 trials. Primary measure of treatment efficacy was the proportion of patients with a good stroke outcome, defined as a modified Rankin Score of 0 or 1 (symptom free or residual symptoms without loss of activity) at 3-6 months. Symptomatic intracranial hemorrhage within 7 days of treatment, fatal intracranial hemorrhage within 7 days, and 90-day mortality were assessed as secondary outcomes.

Overall, 2,110 (31%) of 6,756 patients achieved a good stroke outcome at 3-6 months. Alteplase resulted in greater odds of a good outcome, with earlier treatment resulting in a greater proportional benefit (p=0.016). The time at which alteplase was estimated to have no effect was 6.3 hours (95% Confidence Interval [CI] 5.0-13.8). Alteplase treatment resulted in a good outcome for 259 (32.9%) of 787 patients treated within 3.0 hours vs. 176 (23.1%) of 762 controls (Odds Ration [OR] 1.75, 95% CI 1.35-2.27); 485 (35.3%) of 1,375 patients treated between 3.0-4.5 hours vs. 432 (30.1%) of 1,437 controls (OR 1.26, 95% CI 1.05-1.51); and 401 (32.5%) of 1,229 patients treated greater than 4.5 hours vs. 357 (30.6%) of 1,166 controls (OR 1.15, 95% CI 0.95-1.40). All treatment benefits were similar regardless of patient age or stroke severity. 231 (6.8%) of 3,391 alteplase patients experienced type 2 parenchymal hemorrhages as compared to 44 (1.3%) of 3,365 controls (OR 5.55, 95% CI 4.01-7.70, p<0.0001) within 7 days, and 91 (2.7%) alteplase patients vs. 13 (0.4%) controls experienced fatal intracranial hemorrhage (OR 7.14, 95% CI 3.98-12.79, p<0.0001). The increase in risk of fatal intracranial hemorrhage was similar regardless of delay in treatment, age, or stroke severity.

More from this author: Improved hematologic cancer survival in Europe over a 15 year period [EUROCARE-5 study];Vitamin D may reduce the risk of hypertension;Schizophrenia linked with higher rates of violence, suicide, and early mortality;Overall improvement in management of high blood pressure between 1994 and 2011;Link between early life antibiotic use, asthma exacerbations, and impaired viral immunity 

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: alteplasestroketpa
Previous Post

One-time telephone interventions have little effect on drug abuse

Next Post

BCG vaccine protective against active tuberculosis in children

RelatedReports

Appropriate use criteria for angiography may frequently miss obstructive coronary artery disease
Cardiology

Bivalirudin during and post-percutaneous coronary intervention reduces bleeding and mortality compared to heparin monotherapy

December 6, 2022
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: the New Cost of Insulin, Beyond IVF, the Spotlight on RSV and Influenza, and Theranos Founder Sentenced to 11 Years!

November 30, 2022
#VisualAbstract: Intensive blood pressure control post-endovascular thrombectomy after acute ischemic stroke linked with worse clinical outcomes
StudyGraphics

#VisualAbstract: Intensive blood pressure control post-endovascular thrombectomy after acute ischemic stroke linked with worse clinical outcomes

November 24, 2022
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Personalized cooler dialysate does not reduce cardiovascular events for hemodialysis patients

November 23, 2022
Next Post
Pro-vaccine messages not associated with increased vaccination intent

BCG vaccine protective against active tuberculosis in children

ACP endorses polysomnography over portable monitors for diagnosing sleep apnea

ACP endorses polysomnography over portable monitors for diagnosing sleep apnea

Adjuvant radiotherapy reduces recurrence of ductal carcinoma; no effect on long-term prognosis

PALB2 mutations shown to be important risk factor for breast cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
  • Homicide deaths are on the rise for children living in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options